Figure 5.

NSC-EXOs loaded with miR-124-3p inhibit tumor growth in vivo. (A) Nude mice were injected with subcutaneous xenografts of U87 glioma cells, followed by euthanization after 3-week treatment using NSC-EXOs-miR-124-3p or PBS (twice per week). (B and C) Tumor weight and volume were measured after the 3-week treatment. (D) The expression of FLOT2 was measured in mouse tumors using reverse transcription-quantitative PCR. (E) FLOT2 and AKT1 protein expression in mouse tumors were detected using western blot analysis. Data are presented as the mean ± SD of three independent experiments. ^*P<0.05 and ^**P<0.01, vs. control orEXO-miR-124-3p group. (F) The expression of hsa-miR-124 was significantly decreased in gliomas according to data from miRCancer (http://mircancer.ecu.edu/index.jsp). (G) The expression of FLOT2 was significantly increased in GBM tissues, and the overall survival of patients with GBM with a high FLOT2 expression was significantly decreased (data were from the GEPIA database; http://gepia.cancer-pku.cn/index.html). NSC, neural stem cell; EXOs, exosomes; FLOT2, flotillin 2; GBM, glioblastoma multiforme.